SCHEMBL73410

SCHEMBL73410

CCOC(=O)c1cc2cccc(OC)c2o1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.68
RECQL P46063 1/20 0.68
KMT2A Q03164 4/20 0.66
ALDH1A1 P00352 2/20 0.66
RAB9A P51151 4/20 0.61
NPC1 O15118 3/20 0.61
MEN1 O00255 3/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
HTT P42858 2/20 0.59
MAPT P10636 2/20 0.59
POLB P06746 2/20 0.55
L3MBTL1 Q9Y468 1/20 0.53
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA3 P07451 1/20 0.52
CA4 P22748 1/20 0.52
CA6 P23280 1/20 0.52
CA5A P35218 1/20 0.52
CA7 P43166 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5584678 0.85 LMNA (0.75) LMNARECQLKMT2AALDH1A1RAB9A
SCHEMBL3061600 0.85 LMNA (0.49) LMNARECQLKMT2AALDH1A1RAB9A
SCHEMBL4675984 0.84 MAOA (0.68) LMNARECQLKMT2AALDH1A1RAB9A
SCHEMBL5311626 0.84 MAOA (0.53) LMNARECQLKMT2AALDH1A1RAB9A
SCHEMBL27297400 0.83 KMT2A (0.53) LMNARECQLKMT2AALDH1A1RAB9A
SCHEMBL7469464 0.83 MAOB (0.52) LMNARECQLKMT2AALDH1A1RAB9A
SCHEMBL2031480 0.83 KMT2A (0.74) KMT2AALDH1A1RAB9ANPC1MEN1
SCHEMBL7553333 0.83 AKR1B1 (0.53) LMNARECQLKMT2AALDH1A1MEN1
SCHEMBL931020 0.82 MAOB (0.51) LMNARECQLKMT2AALDH1A1RAB9A
SCHEMBL17842824 0.82 MAOB (0.51) LMNARECQLKMT2AALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102997991-A Ultraviolet detection device LIYANG PRODUCTIVITY PROMOTION CT 2013-03-27 CN claimed
CN-112041296-B Aminoacetamides containing benzooxy alicyclic structures and uses thereof 上海璃道医药科技有限公司 2023-12-29 CN disclosed
WO-2022213932-A1 PYRROLOPYRIMIDINONE COMPOUND AND APPLICATION THEREOF 广州必贝特医药股份有限公司 2022-10-13 WO disclosed
CN-114761410-A Pyrrolopyrimidinone compounds and application thereof 广州必贝特医药股份有限公司 2022-07-15 CN disclosed
CN-112041296-A Aminoacetamides containing benzo-oxy-alicyclic structure and use thereof 上海璃道医药科技有限公司 2020-12-04 CN disclosed
EP-1831227-B1 NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS GLENMARK PHARMACEUTICALS SA (CH) 2013-06-19 EP disclosed
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
CN-102997991-A Ultraviolet detection device LIYANG PRODUCTIVITY PROMOTION CT 2013-03-27 CN disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
WO-2012068702-A1 BENZO 5-MEMBERED UNSATURATED HETEROCYCLIC COMPOUNDS AND PREPARATION METHODS THEREOF 中国医学科学院医药生物技术研究所 (CN) 2012-05-31 WO disclosed
EP-1093367-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-04-25 EP disclosed
US-6194396-B1 ANTIALLERGENS; ANTIINFLAMMATION AGENTS; AUTOIMMUNE DISEASE; ANTISHOCK AGENTS; ANALGESICS; E.G., A 4 OR 7-PHENYLALKYLENE-OXYBENZIMIDAZOLE UNSUBSTITUTED OR SUBSTITUTED IN THE 1,2,3-POSITION WITH AN OXY, AMINO AND/OR THIO GROUP FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-02-27 US disclosed
EP-1029860-A1 BENZOFURAN DERIVATIVES KYOWA HAKKO KOGYO CO., LTD. (JP) 2000-08-23 EP disclosed
US-6083961-A FOR PREVENTION AND/OR TREATMENT OF BRADYKININ OR ITS ANALOGUES MEDIATED DISEASES SUCH AS ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASE, SHOCK, PAIN FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-07-04 US disclosed
US-6043264-A A THROMBOXANE A2 RECEPTOR ANTAGONIST FOR TREATING HYPERTENSION, THROMBOSIS, ISCHEMIC HEART DISEASES, CIRCULATORY DISEASES, ARTERIOSCLEROSIS, PLATELET FUNCTION DISORDER, HYPERLIPIDEMIA, NEPHRITIS OR ASTHMA TORAY INDUSTRIES, INC. (JP) 2000-03-28 US disclosed
WO-1999066925-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1999-12-29 WO disclosed
EP-0774462-A1 HETEROCYCLIC COMPOUND FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-05-21 EP disclosed
EP-0751126-A1 BENZENE-FUSED HETEROCYCLIC DERIVATIVE AND USE OF THE SAME TORAY INDUSTRIES, INC. (JP) 1997-01-02 EP disclosed
EP-0020391-A1 SUBSTITUTED ACETIC ACID ESTERS SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1981-01-07 EP disclosed
WO-1980000563-A1 SUBSTITUTED ACETIC ACID ESTERS SOREX LTD (GB) 1980-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP LMNA 3028/4885RECQL 3473/4885KMT2A 1298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.